Nventa Biopharmaceuticals receives new U.S. patent

Nventa Biopharmaceuticals Corporation has announced that the U.S. Patent and Trademark Office has issued Patent Number 7,262,014 to Nventa covering compositions and methods for inducing or enhancing immune responses to a human papillomavirus (HPV) antigen with or without the use of an adjuvant.

The Company's CoVal(TM) HPV protein fusions are being developed to treat patients with HPV-related diseases.

This new U.S. patent provides for a method of treating a tumor expressing an HPV antigen through the administration of an effective amount of a composition comprised of an HPV antigen joined or fused to a stress protein. This patent provides additional patent exclusivity for HspE7, the Company's investigational therapeutic vaccine, and future HPV fusions through February 2019.

Gregory M. McKee, President and Chief Executive Officer at Nventa commented: "The issuance of this patent protecting the use of our HPV CoVal(TM) protein fusions to treat HPV-related diseases strengthens our intellectual property portfolio and, we believe, adds further value to our HspE7 program, which is currently in Phase 1 clinical development."